ImmuCell Net Debt from 2010 to 2026

ICCC Stock

USD 6.49 0.14 2.11%

ImmuCell's Net Debt is increasing over the years with slightly volatile fluctuation. Overall, Net Debt is expected to go to about 13.7 M this year. Net Debt is the total debt of ImmuCell minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1989-06-30

Previous Quarter

8.3 M

Current Value

9.7 M

Quarterly Volatility

3.8 M

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check ImmuCell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuCell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 686.7 K or Total Revenue of 32 M, as well as many indicators such as Price To Sales Ratio of 1.69, Dividend Yield of 0.0 or PTB Ratio of 1.8. ImmuCell financial statements analysis is a perfect complement when working with ImmuCell Valuation or Volatility modules.

Build AI portfolio with ImmuCell Stock

Check out the analysis of ImmuCell Correlation against competitors.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

Analyzing ImmuCell's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing ImmuCell's current valuation and future prospects.

Latest ImmuCell's Net Debt Growth Pattern

Below is the plot of the Net Debt of ImmuCell over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. ImmuCell's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmuCell's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

ImmuCell Net Debt Regression Statistics

	Arithmetic Mean	4,412,702
	Geometric Mean	2,128,199
	Coefficient Of Variation	132.82
	Mean Deviation	4,940,172
	Median	2,128,173
	Standard Deviation	5,860,974
	Sample Variance	34.4T
	Range	17.9M
	R-Value	0.82
	Mean Square Error	11.8T
	R-Squared	0.68
	Significance	0.000049
	Slope	955,638
	Total Sum of Squares	549.6T

ImmuCell Net Debt History

	2026	13.7 M
	2025	13 M
	2024	11.3 M
	2023	15.7 M
	2022	6.7 M
	2021	89 K
	2020	2.8 M

Other Fundumenentals of ImmuCell

Net Debt To E B I T D A

ImmuCell Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.76	-0.72	0.87	0.96	0.86	0.85	0.16	0.69	0.97	0.89	0.93	0.71	0.83	-0.65	0.71	0.96	0.89	0.89	-0.9	0.83	0.84	0.77	0.83
Total Stockholder Equity	0.98		0.63	-0.6	0.81	0.89	0.87	0.77	0.25	0.68	0.94	0.87	0.93	0.59	0.81	-0.58	0.59	0.94	0.9	0.87	-0.92	0.77	0.83	0.8	0.78
Net Debt	0.76	0.63		-0.87	0.78	0.9	0.51	0.89	-0.16	0.49	0.79	0.71	0.68	0.88	0.64	-0.63	0.88	0.77	0.6	0.72	-0.58	0.8	0.57	0.38	0.73
Retained Earnings	-0.72	-0.6	-0.87		-0.88	-0.85	-0.68	-0.85	0.32	-0.42	-0.84	-0.55	-0.62	-0.93	-0.65	0.67	-0.93	-0.65	-0.58	-0.73	0.47	-0.75	-0.77	-0.62	-0.9
Net Receivables	0.87	0.81	0.78	-0.88		0.91	0.84	0.81	-0.13	0.62	0.95	0.65	0.74	0.8	0.67	-0.64	0.8	0.8	0.68	0.79	-0.67	0.74	0.83	0.74	0.9
Total Liab	0.96	0.89	0.9	-0.85	0.91		0.78	0.92	0.02	0.65	0.96	0.86	0.88	0.83	0.8	-0.7	0.83	0.94	0.82	0.87	-0.81	0.85	0.8	0.67	0.86
Total Current Assets	0.86	0.87	0.51	-0.68	0.84	0.78		0.66	0.02	0.66	0.89	0.6	0.75	0.66	0.63	-0.39	0.66	0.71	0.73	0.72	-0.74	0.61	0.87	0.84	0.83
Short Term Debt	0.85	0.77	0.89	-0.85	0.81	0.92	0.66		-0.06	0.45	0.87	0.8	0.87	0.79	0.86	-0.62	0.79	0.83	0.79	0.91	-0.71	0.95	0.7	0.6	0.83
Intangible Assets	0.16	0.25	-0.16	0.32	-0.13	0.02	0.02	-0.06		0.5	0.04	0.28	0.19	-0.33	0.18	0.04	-0.33	0.25	0.28	0.04	-0.55	0.05	-0.15	-0.08	-0.21
Accounts Payable	0.69	0.68	0.49	-0.42	0.62	0.65	0.66	0.45	0.5		0.66	0.56	0.5	0.48	0.34	-0.32	0.48	0.63	0.57	0.39	-0.82	0.41	0.42	0.34	0.46
Common Stock	0.97	0.94	0.79	-0.84	0.95	0.96	0.89	0.87	0.04	0.66		0.8	0.88	0.79	0.81	-0.67	0.79	0.91	0.84	0.89	-0.82	0.83	0.88	0.8	0.91
Long Term Debt	0.89	0.87	0.71	-0.55	0.65	0.86	0.6	0.8	0.28	0.56	0.8		0.91	0.54	0.82	-0.64	0.54	0.93	0.94	0.8	-0.86	0.85	0.66	0.62	0.71
Treasury Stock	0.93	0.93	0.68	-0.62	0.74	0.88	0.75	0.87	0.19	0.5	0.88	0.91		0.58	0.94	-0.57	0.58	0.92	0.92	0.95	-0.86	0.88	0.76	0.74	0.76
Property Plant Equipment	0.71	0.59	0.88	-0.93	0.8	0.83	0.66	0.79	-0.33	0.48	0.79	0.54	0.58		0.55	-0.61	1.0	0.62	0.54	0.65	-0.47	0.68	0.71	0.53	0.82
Current Deferred Revenue	0.83	0.81	0.64	-0.65	0.67	0.8	0.63	0.86	0.18	0.34	0.81	0.82	0.94	0.55		-0.62	0.55	0.84	0.86	0.96	-0.75	0.89	0.74	0.72	0.74
Short Term Investments	-0.65	-0.58	-0.63	0.67	-0.64	-0.7	-0.39	-0.62	0.04	-0.32	-0.67	-0.64	-0.57	-0.61	-0.62		-0.61	-0.7	-0.61	-0.62	0.46	-0.58	-0.67	-0.6	-0.66
Net Tangible Assets	0.71	0.59	0.88	-0.93	0.8	0.83	0.66	0.79	-0.33	0.48	0.79	0.54	0.58	1.0	0.55	-0.61		0.62	0.54	0.65	-0.47	0.68	0.71	0.53	0.82
Long Term Debt Total	0.96	0.94	0.77	-0.65	0.8	0.94	0.71	0.83	0.25	0.63	0.91	0.93	0.92	0.62	0.84	-0.7	0.62		0.87	0.87	-0.88	0.82	0.74	0.67	0.75
Capital Surpluse	0.89	0.9	0.6	-0.58	0.68	0.82	0.73	0.79	0.28	0.57	0.84	0.94	0.92	0.54	0.86	-0.61	0.54	0.87		0.85	-0.87	0.86	0.78	0.78	0.8
Deferred Long Term Liab	0.89	0.87	0.72	-0.73	0.79	0.87	0.72	0.91	0.04	0.39	0.89	0.8	0.95	0.65	0.96	-0.62	0.65	0.87	0.85		-0.75	0.9	0.81	0.76	0.82
Long Term Investments	-0.9	-0.92	-0.58	0.47	-0.67	-0.81	-0.74	-0.71	-0.55	-0.82	-0.82	-0.86	-0.86	-0.47	-0.75	0.46	-0.47	-0.88	-0.87	-0.75		-0.72	-0.6	-0.58	-0.61
Short Long Term Debt	0.83	0.77	0.8	-0.75	0.74	0.85	0.61	0.95	0.05	0.41	0.83	0.85	0.88	0.68	0.89	-0.58	0.68	0.82	0.86	0.9	-0.72		0.69	0.62	0.82
Net Invested Capital	0.84	0.83	0.57	-0.77	0.83	0.8	0.87	0.7	-0.15	0.42	0.88	0.66	0.76	0.71	0.74	-0.67	0.71	0.74	0.78	0.81	-0.6	0.69		0.95	0.93
Net Working Capital	0.77	0.8	0.38	-0.62	0.74	0.67	0.84	0.6	-0.08	0.34	0.8	0.62	0.74	0.53	0.72	-0.6	0.53	0.67	0.78	0.76	-0.58	0.62	0.95		0.86
Capital Stock	0.83	0.78	0.73	-0.9	0.9	0.86	0.83	0.83	-0.21	0.46	0.91	0.71	0.76	0.82	0.74	-0.66	0.82	0.75	0.8	0.82	-0.61	0.82	0.93	0.86

Click cells to compare fundamentals

About ImmuCell Financial Statements

ImmuCell stakeholders use historical fundamental indicators, such as ImmuCell's Net Debt, to determine how well the company is positioned to perform in the future. Although ImmuCell investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuCell's assets and liabilities are reflected in the revenues and expenses on ImmuCell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuCell. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	13 M	13.7 M
Net Debt To EBITDA	9.57	9.36

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:

How To Invest In ImmuCell

Details

Is ImmuCell Stock a good investment?

Details

What is ImmuCell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of ImmuCell Correlation against competitors.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Will Biotechnology sector continue expanding? Could ImmuCell diversify its offerings? Factors like these will boost the valuation of ImmuCell. Market participants price ImmuCell higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ImmuCell data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

(0.63)

Earnings Share

0.21

Revenue Per Share

3.22

Quarterly Revenue Growth

0.178

Return On Assets

0.0302

Understanding ImmuCell requires distinguishing between market price and book value, where the latter reflects ImmuCell's accounting equity. The concept of intrinsic value - what ImmuCell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ImmuCell's price substantially above or below its fundamental value.

Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ImmuCell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

ImmuCell Net Debt from 2010 to 2026

Latest ImmuCell's Net Debt Growth Pattern

ImmuCell Net Debt Regression Statistics

ImmuCell Net Debt History

Other Fundumenentals of ImmuCell

ImmuCell Net Debt component correlations

About ImmuCell Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY